Ana (Hrsg.) Martinez

Emerging Drugs and Targets for Alzheimer's Disease

Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism

Ebook (PDF Format)

Alzheimer's disease is the most prevalent type of neurodegenerative disorder in the elderly. A recent study from Bloomberg School of Public Health estimated that more than 26 million people worldwide were living with the disease in 2006 and that the global prevalence of the disease will grow to more than 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could… Mehr

CHF 200.00

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen
Versandkostenfrei

Produktdetails

ISBN: 978-1-84973-106-5
EAN: 9781849731065
Produktnummer: 35940431
Verlag: Royal Society Of Chemistry
Sprache: Englisch
Erscheinungsjahr: 2010
Seitenangabe: 287 S.
Plattform: PDF
Masse: 0 KB

Über den Autor

Ana Martinez obtained her PhD in Organic Chemistry from the Complutense University of Madrid before becoming a researcher at the Medicinal Chemistry Institute of the Spanish National Council for Research (CSIC). Since 1995, her interests have focused on neurodegenerative disorders and she has led numerous research projects on the medicinal chemistry and rational drug design with the aim of finding new treatments for Alzheimer's disease. In February 2002, she joined NeuroPharma (now NOSCIRA) as R&D Director where she led projects from the discovery of potential new therapies to the final proof of concept in animal models. In February 2008, she returned to her academic position at the Medicinal Chemistry Institute (CSIC) leading several projects on neurodegenerative disease therapies and acting as an external scientific advisor to a number of pharmaceutical companies. Her main areas of research currently involve GSK-3 inhibitors and dual binding site acetylcholinesterase inhibitors. She has authored over a hundred and fifty scientific publications and has more than twenty active patents in the field.